Aravive (ARAV) delivered earnings and revenue surprises of 33.33% and 98.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 24.11% and 0.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aravive (ARAV) delivered earnings and revenue surprises of -39.39% and 298.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 25% and 32.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
/PRNewswire/ -- USA News Group - A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this...
FN Media Group Presents USA News Group News Commentary  Vancouver, BC –December 1, 2022 – USA News Group  – A series of new Fast Track designations have been handed out by the United States...
USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry of activity in the markets for the worthy...
Aravive (ARAV) delivered earnings and revenue surprises of 20.31% and 298.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?